BA
Bal Pharma Ltd (BALPHARMA)
₹83.21
Mkt cap
₹145 Cr
P/E ratio
18.30
P/B
1.52
Div yield
1.32%
ROE
7.79%
ROCE
9.75%
EPS (TTM)
₹4.55
Book value
₹55
52W range
60–125
Sector
Healthcare
Price history
Previous close
Incorporated in 1987, Bal Pharma Ltd does manufacturing and selling of pharmaceutical products and related services [1]
NSE BALPHARMABSE 524824
Health check
Mixed
ValuationCheap
ProfitabilityWeak
GrowthModerate
TechnicalsNeutral
52-week range
−33.22% from high₹83
₹60+38.68% from low₹125
Current
₹83.21
Prev close
₹84.61
Day
−1.65%
Price performance
1D
−1.96%
1W
−8.79%
1M
−1.92%
3M
−4.28%
6M
−2.56%
1Y
+3.17%
YTD
+13.60%
Financials
Revenue, profit & margin
P/E ratio
18.3×
BALPHARMA is 46% below the sector median of 34.0×
BALPHARMA18.3×
Sector median34.0×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 92.54 | 81.66 | 94.63 | 74.36 | 73.69 | 73.15 | 81.88 | 65.87 | 74.02 | 87.69 | 84.08 | 88.62 | 89.95 | |
| YoY Sales growth | +22.88% | +6.58% | +14.77% | +5.64% | -20.37% | -10.42% | -13.47% | -11.42% | +0.45% | +19.88% | +2.69% | +34.54% | +21.52% | |
| Expenses | 84.84 | 73.87 | 85.03 | 67.89 | 66.00 | 65.40 | 74.24 | 59.81 | 68.29 | 78.15 | 73.50 | 80.67 | 81.29 | |
| Operating Profit | 7.70 | 7.79 | 9.60 | 6.47 | 7.69 | 7.75 | 7.64 | 6.06 | 5.73 | 9.54 | 10.58 | 7.95 | 8.66 | |
| OPM % | 8.32% | 9.54% | 10.14% | 8.70% | 10.44% | 10.59% | 9.33% | 9.20% | 7.74% | 10.88% | 12.58% | 8.97% | 9.63% | |
| Other Income | 0.14 | 0.10 | 2.45 | 0.82 | -0.20 | 0.51 | 1.08 | 0.72 | 1.12 | 0.33 | -0.24 | 0.44 | 1.63 | |
| Interest | 3.82 | 3.66 | 4.14 | 4.24 | 3.65 | 5.01 | 3.95 | 4.05 | 3.86 | 4.85 | 4.06 | 4.47 | 4.98 | |
| Depreciation | 2.42 | 2.96 | 2.16 | 2.43 | 2.48 | 2.69 | 2.18 | 2.52 | 2.27 | 3.23 | 3.06 | 2.78 | 3.38 | |
| Profit before tax | 1.60 | 1.27 | 5.75 | 0.62 | 1.36 | 0.56 | 2.59 | 0.21 | 0.72 | 1.79 | 3.22 | 1.14 | 1.93 | |
| Tax % | 39.38% | 33.07% | 3.65% | 58.06% | 23.53% | 7.14% | -108.88% | 0.00% | 0.00% | 0.00% | -12.11% | 0.00% | 25.91% | |
| Net Profit | 0.97 | 0.85 | 5.53 | 0.26 | 1.04 | 0.52 | 5.41 | 0.21 | 0.72 | 1.79 | 3.60 | 1.13 | 1.43 | |
| EPS in Rs | 0.61 | 0.56 | 3.46 | 0.16 | 0.65 | 0.30 | 3.41 | 0.13 | 0.45 | 1.12 | 2.25 | 0.70 | 0.89 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202650.87%Promoter
Promoters50.87%
FIIs0.28%0.13
Public48.87%0.12
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,880.00 | 36.66 | 4,51,075 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,442.00 | 88.89 | 3,03,749 | 0.26% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,670.00 | 81.82 | 1,77,632 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,424.00 | 97.75 | 1,30,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,189.90 | 26.20 | 1,18,693 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,380.00 | 41.17 | 1,15,267 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,391.80 | 36.21 | 1,12,442 | 0.93% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Bal Pharma | ₹90.94 | 18.30 | 145 | 1.32% | 1 | +100.00% | 90 | +21.52% | 9.75% |
| Median: 160 Co. | ₹465.83 | 33.99 | 2,012 | 0.08% | 13 | +33.53% | 179 | +20.92% | 14.94% |
Filings
Annual reports15
Concall transcripts3
Credit ratings6
Announcements5
Newspaper Publications - Unaudited Financial Results 30Th September 2026 12 Nov - Newspaper publication of unaudited Q2 and half-year 2026-27 financial results, following November 11 board meeting.Statement Of Deviation & Variation : Statement Of Utilization Of Issue Proceeds Raised Through Preferential Issue Of Warrants Ref: Regulation 32(1) Of SEBI (LODR) Regulations ,2015. 11 Nov - Bal Pharma reports no deviation in Rs2.10 crore warrant proceeds for quarter ended September 30, 2026.Board Meeting Outcome for Outcome Of Board Meeting 11 Nov - Board approved Q2 and H1 FY2026-27 results; ₹2.10 crore warrant proceeds remain unutilized, no deviation.Unaudited Standalone And Consolidated Financial Results For The Second Quarter And Half Year Ended On 30Th September, 2026 Along With The Limited Review Report 11 Nov - Bal Pharma reported Q2 FY27 results on 11 Nov 2026; standalone profit ₹152.71 lakh, no warrant utilization.Board Meeting Intimation for For Considering Inter-Alia The Unaudited (Standalone And Consolidated) Financial Result Of The Company For The Second Quarter Ended 30Th September 2026 3 Nov - Board meeting on November 11, 2026 to approve Q2 and half-year FY27 results.






